17:34 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Perceptive leads Lyra's $29.5M series B

Ears, nose and throat disease company Lyra Therapeutics Inc. (Watertown, Mass.) raised $29.5 million in a series B round led by Perceptive Advisors. Fellow new investors RA Capital, ArrowMark Partners and Soleus Capital also participated,...
11:01 , Sep 26, 2018 |  BC Extra  |  Financial News

Perceptive leads Lyra’s $29.5M series B

Ears, nose and throat disease company Lyra Therapeutics Inc. (Watertown, Mass.) raised $29.5 million in a series B round led by Perceptive Advisors. Fellow new investors RA Capital, ArrowMark Partners and Soleus Capital also participated,...
17:26 , Aug 17, 2018 |  BC Week In Review  |  Company News

Perrigo to separate its generics business

Perrigo Co. plc (NYSE:PRGO; Tel Aviv:PRGO) said it plans to separate its prescription generics business to focus on its consumer healthcare products. The company expects the transaction -- which could include a separation to shareholders,...
18:37 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Glenmark's Ryaltris meets in Phase III for seasonal allergic rhinitis

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported data from a Phase III trial in 1,180 patients with seasonal allergic rhinitis showing that twice-daily Ryaltris mometasone/olopatadine met the primary endpoint of improving average morning and evening patient-reported...
19:11 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

Glenmark's Ryaltris meets in Phase III for perennial allergic rhinitis

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported top-line data showing that twice-daily Ryaltris mometasone/olopatadine (formerly GSP 301) met the primary safety endpoint and a secondary efficacy endpoint in a Phase III trial to treat perennial allergic...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

Indacaterol/glycopyrronium bromide/mometasone fuorate: Phase III started

Vectura and Sosei said Novartis began a double-blind, international Phase III trial to compare 2 dose levels of inhaled QVM149 vs. 2 dose levels of Novartis’ inhaled indacaterol/mometasone furoate ( QMF149 ) or salmeterol xinafoate...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

Dupilumab: Phase IIa data

Top-line data from a double-blind, international Phase IIa trial in 60 patients with moderate to severe chronic sinusitis with nasal polyps who did not respond to intranasal corticosteroids showed that once-weekly subcutaneous dupilumab met the...
07:00 , Aug 4, 2014 |  BioCentury  |  Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
07:00 , Jul 28, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained $5.79 to $167.04 last week after EMA accepted and granted accelerated assessment to an MAA for asfotase alfa to treat hypophosphatasia (HPP). The company expects to complete a...
23:55 , Jul 24, 2014 |  BC Extra  |  Financial News

Intersect raises $55 million in IPO

Intersect ENT Inc. (NASDAQ:XENT) was up $1.92 (17%) to $12.92 on its first day of trading Thursday after raising $55 million through the sale of 5 million shares at $11 in an IPO. The $11...